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after correction of baseline data to exclude the influence ofRenal function and outcome of PTRA and stenting for athero-
the expected regression to the mean.sclerotic renal artery stenosis.
Conclusions. Patients with atherosclerotic RAS fulfilling strictBackground. Prior studies of percutaneous transluminal re-
criteria of severity may have significant improvements in BPnal artery angioplasty and stenting (PTRAS) for atherosclerotic
one year after PTRAS but only modest in GFR. The initialrenal artery stenosis (RAS) have shown that renal function is
GFR may anticipate whether the benefits in the outcome willimproved in about 25%, stabilizes in about 40%, but worsens
be in renal function enhancement (those with an initially de-in about 25% of patients. The factors predicting benefit remain
pressed GFR) or in hypertension control (those with an initiallycontroversial. We tested the hypothesis that the baseline glo-
normal or mildly impaired GFR).merular filtration rate (GFR) predicts the changes in GFR and
blood pressure (BP) after PTRAS.
Methods. Treated hypertensive patients with positive renal
color-coded duplex Doppler velocimetry and clinical criteria Renal artery stenosis (RAS) causing renovascular dis-
were screened by arteriography. Patients (N 105) were included
ease was considered a rare cause of secondary hyperten-if they had an RAS 70%, a transluminal pressure gradient
sion. However, with improvements in techniques for30 mm Hg and, they had more than 100 days of follow-up.
GFR was calculated from the serum creatinine concentration screening and with the widespread use of vascular im-
(SCr). Patients were divided by baseline GFR into subgroups aging, it is now recognized that 40 to 50% of patients
with normal to mildly impaired (N  52) or moderately to with occlusive disease of the lower limb [1] and 15 to 30%
severely impaired (N  53) initial GFR, according to a GFR of patients with coronary artery disease have identifiable50 or 50 mL · min1 respectively. All received PTRAS.
RAS [2]. Reports of patients with established, or newlyResults. For the entire group, after a mean follow-up period
diagnosed, end-stage renal disease (ESRD) indicate aof 371 days, there were significant reductions in systolic and
diastolic BP (before, 160  26/91  12 vs. after, 145  20/83  prevalence of RAS of 10 to 22% [3, 4]. Some 3 to 30%
10 mm Hg, respectively; mean SD; P 0.0001), and a modest of patients with atherosclerotic RAS show a progressive
increase in the calculated GFR (before, 54  26 vs. after, 62  loss of renal mass over three to five years [5]. A number28 mL · min1; meanSD; P 0.007). However, in the subgroup
suffer renal artery occlusion, which may prevent subse-of patients with an initially lower GFR there was a significant
quent intervention and often heralds a sharp decline inincrease in the calculated GFR (from 33.3  10 to 54  24
mL · min1; mean  SD; P  0.0001) despite no significant renal function. Percutaneous transluminal renal angio-
change in BP (161  27/90  12 vs. 151  21/86  12; P  plasty and stenting (PTRAS) provides a much less inva-
NS). In contrast, in the subgroup with an initially higher GFR, sive technique than surgery, yet also has a high probabil-
there were significant (P  0.0001) reductions in systolic BP
ity of correction of the stenosis. These considerations(from 159  25 to 138  16 mm Hg) and diastolic BP (from
have led clinicians to be more aggressive in this search91  11 to 81  9 mm Hg), but no significant change in the
calculated GFR (from 75  21 to 70.2  30 mL · min1; P  for RAS. However, recent controlled clinical trials have
NS). The significance of GFR variation in subgroups remained cast doubt on the efficacy of angioplasty for RAS and
have documented a significant rate of complications. Im-
provements in blood pressure (BP) or glomerular filtra-Key words: renal vascular hypertension, ischemic nephropathy, hyper-
tion rate (GFR) were not detected in the DRASTICtension, glomerular filtration rate, percutaneous transluminal renal
artery stenting. trial in hypertensive patients with RAS50% who were
randomized to PTRA, compared to medical therapy,Received for publication October 5, 2001
over a one year period of follow-up [6]. Nevertheless,and in revised form August 28, 2002
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indicates that 25 to 30% had an improvement in GFR, tion recommendations [10]. Reported values for each
subject are the average of three separate readings.45 to 50% had a stable GFR, whereas 20 to 25% had a
decline in GFR at follow-up [7, 8]. The failure to show Renal function was assessed from measurements of
serum creatinine concentration (SCr) and application ofstatistically significant effects of intervention on GFR in
individual studies was due to a similar number of those the Cockroft and Gault formula [11] to estimate the
glomerular filtration rate (GFR; mL · min1) accordingwho improved or who deteriorated [7]. Therefore, it
becomes critical to define subgroups of patients with to the SCr (mg · dL1), weight (kg), age (years) and gender
RAS who may have an improvement in BP or GFR after of the patient:
intervention.
GFR (males)  [(140 – age)  body weight]/(SCr  72)We tested the hypothesis that, in selected patients with
quite severe RAS, the preexisting level of renal function GFR (females)  Value for males  0.85
might predict a group of patients who will experience a
Renal arteriography was performed through a femoralfavorable GFR and/or BP response to intervention with
artery access with a guided 8-French catheter placed inPTRAS.
the aorta to study selectively all renal arteries. Thereafter,
if a renal artery stenosis 70% was detected, further
METHODS views were undertaken (in the anteroposterior and coro-
nal planes) to confirm the degree of luminal stenosisThe Ethical Review Board of the Favaloro Foundation
from the arteriographic photographs. The catheter wasin Buenos Aires, Argentina where all of these studies
advanced across the stenosis and the pressure gradientwere conducted, authorized the study. Informed consent
established, and in those cases with critical RAS thewas required in all participants. Patients selected were
thinnest available catheter was employed. Whenever athose at risk for RAS according to clinical criteria (JNC
stenosis was considered hemodynamically significantVI stages II-III or resistant hypertension, or associated
(30 mm Hg pressure gradient), PTRA was performedrenal failure or atherosclerotic vascular disease) and a
with a Tittan balloon where the width and length werepositive screening test utilizing renal ultrasound with
selected according to the anatomy of the stenosis. There-color-coded duplex Doppler velocimetry of the renal
after, a Palmaz Schatz stent was implanted over a Cordisarteries (HP SONOS 2500, with 2.5 and 3.5 MHz probes).
balloon, which was inflated to 10 to 12 atmospheres orSingle operator echographic sensitivity and specificity
as necessary to produce a good anatomical result [12].for repeated measurements for stenosis over 60% were
Complications observed after the procedure were twoboth 97% (analysis of 343 arteries). There was a signifi-
cases of bleeding and large inguinal hematoma with ancant correlation between the quantitative estimations of
hematocrit drop of more than 5%, and one case of rightthe degree of RAS by the duplex Doppler velocimetry
perirenal hematoma during a bilateral stenting proce-method with the values obtained subsequently by arteri-
dure managed conservatively without afterward clinicalography (r  0.79, P  0.001). From an initial sample
consequences.of 149 patients, a study group of 105 was obtained with
The following definitions were applied:significant atherosclerotic renovascular stenosis (detailed
later in this article), and a follow-up evaluation after at
least 100 days. A number of 44 patients were excluded Hypertension: systolic blood pressure (SBP) 140
mm Hg and/or diastolic blood pressure (DBP) 90because they (a) had a RAS 70% in arteriography and
did not undergo PTRAS (N  27); (b) received angio- mm Hg, calculated as the average of three separate
blood pressure recordings, or the need for currentplasty without stenting (N  2); (c) were submitted to
surgery (N  2); (d) had a primary stent failure (N  1); antihypertensive therapy.
Significant renal artery stenosis:70% luminal reduc-and (e) were lost to follow-up (N  12). The follow-up
after PTRAS averaged 371 days (median 376, range 100 tion of a renal artery and a pressure gradient of30
mm Hg across the lesion.to 700). Only patients with primary technical success
following PTRAS were included [9]. Inclusion in the study Bilateral renal artery stenosis:50% bilateral luminal
reductions. At variance with the former definition,required at least two clinic visits following the interven-
tion. Routine laboratory tests and a second renal ultra- a lower limit was used only in order to characterize
a subgroup of patients with higher extension of ath-sound study were undertaken in all study patients at the
last of these visits. Blood pressure data were the average erosclerotic renal artery disease suggesting a higher
risk of disease progression, but stenting were limitedvalues obtained before the intervention and at the last
of the follow-up evaluations, both under prescribed anti- only to those defined as significant RAS.
Cure of hypertension: SBP140 mm Hg and DBP90hypertensive treatments. A trained operator measured
BP with a mercury sphygmomanometer after two min- mm Hg in the absence of antihypertensive therapy.
Renal function according to GFR: normal to mildlyutes of sitting, according to the American Heart Associa-
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Table 1. Clinical and laboratory data before intervention
Normal to mildly Moderate to severely
Total impaired renal function impaired renal function
population GFR 50 mL · min1 GFR 50 mL · min1
Number of patients 105 52 53
Age years 5910 599 6011
Gender female/male 42/63 21/31 21/32
SBP mm Hg 16026 15925 16127
DBP mm Hg 9112 9111 9012
Controlled hypertension BP 140/90 26 14 12
Number of antihypertensive drugs used 2.2 1.861 2.430.9b
Serum creatinine mg · dL1 1.670.88 1.030.26 2.290.83
Calculated (Cockroft-Gault) GFR mL · min1 5426 7520.6 33.69.6
Number with 3 risk factorsa 68 33 35
Number with diabetes mellitus 29 15 14
Unilateral/bilateral renal artery lesions 60/45 34/18 26/27
Number with bilateral stents 18 7 11
Number with ostial stenosis 34 13 21
Abbreviations are: SBP, systolic blood pressure; DBP, diastolic blood pressure; GFR, glomerular filtration rate.
aHypertension, diabetes, dyslipidemia, tobacco use, obesity (BMI 27)
bP  0.01, between subgroups using unpaired t test
impaired 50 mL · min1, moderate to severely tensive and receiving drug treatment, but only 26 (25%)
were controlled. Renal artery stenosis was found bilat-impaired 50 mL · min1.
eral in 45 (43%) patients. Of these, 18 (40%) underwentPrimary technical success after PTRAS: residual ste-
bilateral PTRAS. A total number of 123 stents werenosis50% and a pressure gradient5 mm Hg with-
applied and 33% of patients presented with ostial renalout major complications (surgery required or death).
artery stenosis.
Statistical analysis The BP and renal function at baseline before PTRAS
and at follow-up is detailed in Table 2. For the group asData are expressed as mean values  standard devia-
a whole, there was a highly significant reduction in BP,tion. To assess within-patient changes, a paired t test was
a modest, but significant, reduction in SCr, and a conse-applied, or Wilcoxon signed-rank test for paired non-
quent increase in the calculated GFR.normal distributed variables (serum creatinine). The pop-
As shown in Figure 1, it is apparent from the sub-ulation sample was analyzed as a whole and by subgroups
group’s analysis that the outcome of PTRAS divergedselected according to renal function as defined above.
upon the initial level of GFR. Thus, a significant improve-Differences between subgroups were analyzed by unpaired
ment in BP control occurred only in the subgroup witht test. Univariate and multivariate regression analysis
initially higher renal function. Conversely, a reductionand 	2 tests were applied when appropriate (GB-STAT
in the SCr and an improvement in the calculated GFRversion 7.0; Dynamic Microsystems, Inc., Silver Spring,
occurred only in the subgroup with initially more impairedMD, USA). A further analysis of the variation observed
renal function. After application of the correction for re-at follow-up in the calculated GFR was undertaken after
gression toward the mean, the improvement in renal func-correction in baseline GFR for the expected regression
tion in the subgroup of patients with initially impairedtoward the mean (RTM). This analysis was required
renal function remained highly significant (Table 2).because of the selection process of subgroups according
After PTRAS there was a considerable improvementto baseline renal function [13]. For this purpose, the
in hypertension control. Overall, the fraction of patientsShepard and Finison formula was applied [14–16]. A re-
with normotension increased from 25% at baseline topeatability correlation index for GFR of 0.7 was applied.
65% after PTRAS, including 19 patients who were curedDifferences were considered significant at P  0.05.
of hypertension. A reduction in the number or doses of
antihypertensive drugs prescribed was observed in 67%
RESULTS of the patients who still required treatment.
The clinical characteristics of the study population at Univariate regression analysis demonstrated a signifi-
baseline are summarized in Table 1. No differences in cant negative correlation between the baseline GFR and
the analyzed variables were found between subgroups, the follow-up values for SBP (r  0.29, P  0.0026)
with the exception of the number of prescribed antihy- and DBP (r  0.33, P  0.0006). After a multivariate
pertensive drugs, which were higher in the group with stepwise regression analysis including age, baseline sys-
tolic (SBP) and diastolic (DBP) blood pressure, andmore impaired renal function. All patients were hyper-
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Table 2. Blood pressure and renal function before intervention and at follow-up
Paired t test or Wilcoxon (SCr)
Baseline data Follow-up data P value
Total population (N  105)
Systolic blood pressure mm Hg 16026 14520 0.0001
Diastolic blood pressure mm Hg 9112 8310 0.0001
Serum creatinine mg · dL1 1.670.88 1.380.68 0.009
Calculated (Cockroft-Gault) GFR mL · min1 5426 6228 0.007
Subgroup with normal to mildly impaired renal function
(GFR 50 mL ·min1, N  52)
Systolic blood pressure mm Hg 15925 13816 0.0001
Diastolic blood pressure mm Hg 9111 819 0.0001
Serum creatinine mg · dL1 1.030.27 1.210.54 NS
Calculated (Cockroft-Gault) GFR mL · min1 7526 70.230 NS
GFR (basal data) after correction for RTM mL · min1 68.721 70.230 NS
Subgroup with moderate to severely impaired renal function
(GFR 50 mL ·min1, N  50)
Systolic blood pressure mm Hg 16127 15121 NS
Diastolic blood pressure mm Hg 9012 8612 NS
Serum creatinine mg · dL1 2.290.83 1.550.75 0.0001
Calculated (Cockroft-Gault) GFR mL · min1 33.39.6 5424.1 0.0001
GFR (basal data) after correction for RTMa mL · min1 39.259.6 5424.1 0.001
RTM is regression toward the mean.
aCorrected for bias due to RTM by the Shepard and Finison formula [14].
GFR at follow-up as covariates, the relationship between Those with an initially elevated SCr had a significant im-
provement in their calculated GFR, despite no apparentSBP and DBP at follow-up as dependent variables with
benefit in their BP (BP decreased, though non-signifi-baseline GFR remained significant. This indicates that
cantly). In contrast, those with an initially normal SCr had aa low GFR value at baseline emerged as a negative
significant improvement in their BP despite no apparentpredictor of PTRAS to reduce the systolic and diastolic
changes in their calculated GFR. As anticipated, the re-blood pressure at follow-up.
stenosis rate was higher in patients with ostial stenosis,A post-hoc subgroup analysis showed that bilateral
but remained low (14%) after one year of follow-up.renal artery stenosis, which was detected in 45 patients,
The subgroups did not differ in their demographics,apparently did not influence the changes in blood pres-
the levels of systolic and diastolic BP, the presence ofsure or GFR after intervention, although this conclusion
comorbid conditions, risk factors, bilateral RAS, the rateis based on a limited number of patients. In 93% of
of bilateral stenting or the fraction with ostial lesions.patients, renal artery patency after stenting was evalu-
By design, they had significant differences at baseline inated at follow-up using color duplex Doppler velocime-
their levels of renal function. We evaluated whethertry. A re-stenosis was detected in 14 patients (14%). This
these results could be ascribed to the phenomenon ofwas more likely in those with ostial lesions (27 vs. 8%;
regression toward the mean (RTM), since bias will occurP  0.02 by Yates-corrected 	2).
when a population is divided into groups according to
one variable, and measurements are made sequentially
DISCUSSION with that variable as the outcome measure. In this cir-
This study was conducted in 105 patients, who all under- cumstance, even in the absence of a real change, the
went a PTRAS after applying quite strict criteria for RAS data for the two groups will converge [13–16]. Thus,
requiring intervention. They were screened by clinical subsequent trends in the data for each group could be
criteria and by positive renal artery color-coded duplex the effects of selection. The degree of RTM depends on
Doppler velocimetry test. Entry required arteriographic the spontaneous variability of the parameter over time
findings of anatomical RAS 70% and hemodynamic and on the differences between the individual mean val-
significance as evidenced by a gradient in arterial pres- ues of the subgroups from the whole population [13, 16].
sure across the stenosis30 mm Hg. Blood pressure and A statistical correction was made in the baseline calcu-
SCr were evaluated before and at an average of one year lated GFR to compensate for the effects of RTM. Using
after the intervention. The group as a whole had a sig- this correction, the modest increase in the SCr and de-
nificant improvement in their BP and calculated GFR, crease in the calculated GFR after intervention in the
without important clinical complications or individuals subgroup of patients with initially normal renal function
with renal function deterioration. However, the main was judged not statistically significant, while the more
robust improvements in these variables in the subgroupnew findings were disclosed in the subgroup analysis.
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16% of patients with RAS who received only medical
therapy progressed to complete occlusion of the affected
renal artery over one year [5]. Therefore, the overall
gain in the calculated GFR over one year can reasonably
be ascribed to the intervention, rather than to a sponta-
neous improvement. Last, the study conclusions are valid
only for the one-year period during which this group of
patients was observed, and according to a non-standard-
ized antihypertensive treatment. Long-term morbidity
and mortality are important objectives that were not
addressed in this study.
An apparent recent increase in the prevalence of RAS
[7, 20–23] has coincided with a more widespread avail-
ability of PTRA(S). Even the casual finding of RAS at
the time of coronary or ilio-femoral arteriography can
prompt a PTRA(S) in the hope of preserving renal func-
tion or improving control of hypertension. However, re-
cent controlled clinical trials cast doubt on the wisdom
of this practice [24]. The Scottish and Newcastle Renal
Artery Stenosis Collaborative Group randomized 55 pa-
tients [25] and the EMMA trial randomized 49 patients
[26] with RAS to PTRA or aggressive medical therapy.
After six months of follow-up, there were no significant
overall advantages of intervention on BP in either trial.
The DRASTIC study detected no differences in BP or
GFR between patients with RAS followed up for one year
after randomization to PTRA or medical therapy [6].
One reason for the different conclusion from our study
compared to controlled trials is that PTRAS has better
Fig. 1. Blood pressure (BP) and glomerular filtration rate (GFR) results than PTRA alone [9, 12, 19, 21–23, 27–32]. In the
changes after percutaneous transluminal renal arterial angioplasty and present study, the rate of re-stenosis at an average follow-
stenting (PTRAS). Symbols are: ( ) subgroup with GFR 50 mL ·
up of one year was 14%.min1; () subgroup with GFR 50 mL · min1; () baseline GFR
corrected for RTM; **P  0.001, ***P  0.0001. A second reason that may account for differences be-
tween conclusion from this study and the controlled trials
is the selection of patients. The DRASTIC study re-
quired only moderate or severe hypertension and aof patients with initially impaired renal function was
50% RAS. This will include many patients at an earlymaintained at a very high level of statistical significance.
stage of RAS that is not yet functionally significant, dilut-This study has some limitations. First, the GFR was
ing the beneficial effects of PTRA in the overall results.calculated from the Cockcroft and Gault formula rather
In contrast, we used a combination of an anatomicalthan being measured directly by a clearance technique.
criterion of a stenosis of70% and a functional criterionHowever, this method obviates errors due to incomplete
of an arterial pressure gradient 30 mm Hg across theurine collection, and repeated measurements in the same
stenosis, to eliminate patients with less severe RAS whoindividual (as in this study), minimize errors due to
may not derive benefit from the procedure. These inclu-changes in creatinine production [17]. Second, we screened
sion criteria might help select the patients that will bene-for re-stenosis by Doppler rather than by the invasive
fit from PTRAS. On the other hand, as patients notmethod of arteriography. We selected Doppler because
fulfilling the inclusion criteria were not submitted toit is very sensitive for detecting re-stenosis after PTRAS
PTRAS, the possible benefit in these subjects cannot be[18]. Indeed, we found that the degree of RAS estimated
excluded. Another study should be aimed to answer thisby Doppler correlated closely with that measured di-
important point, that is, the relationship of the severityrectly by arteriography. The rates of re-stenosis after
of vascular disease and the subsequent improvement ob-PTRAS are only 25% of those for PTRA alone [19].
tained after PTRAS. To answer this question, the vari-Third, the study lacked a control (untreated) group. Nev-
ables to be assessed should be thresholds of anatomicertheless, previous work has shown that atherosclerotic
RAS tends to be progressive [7, 20]. In a recent study, RAS, trans-stenotic BP gradients, levels of baseline GFR,
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or other markers that could be useful to predict patient with normal renal function studied by split renal function
methods, an improvement in GFR of the post-stenoticoutcome and to be applied in decision-making.
Several other studies have evaluated renal function kidney after angioplasty is offset by a decline in GFR
of the contralateral kidney that limits the beneficial ef-after intervention for atherosclerotic RAS [7, 12, 27, 28].
Among the larger trials, Jensen et al studied 107 patients fects on overall GFR [35]. Discordant effects on GFR
and BP in the group with an initially elevated SCr maywith atherosclerotic RAS over one year following PTRA
[33]. There were significant (P  0.001) reductions in be related to the persistence of residual renal dysfunc-
tion, since the GFR was not normalized after PTRAS.the BP and increases in the GFR. The GFR was measured
from the plasma clearance of (51Cr)–ethylenediamine- Intrarenal vascular disease predicts a poor BP response
to PTRA [12]. Despite the observed BP reduction wastetraacetic acid (EDTA) and increased from 48  24
mL · min1 to 53  27 mL · min1. This is very close to not significant for the subgroup with more severe impair-
ment in renal function, considering the observed reduc-the increase in calculated GFR from 54 to 62 mL · min1
detected in the present series. Watson et al studied renal tion in the drug’s number/dose, a response of lesser mag-
nitude but of clinical value cannot be excluded, althoughfunction from the slope of the reciprocal of SCr over time
in 33 azotemic patients with atherosclerotic RAS before, to confirm this effect a higher number of patients would
be required. In the trials comparing the effects on BPand for 20 months after PTRAS [34]. Renal function,
which was deteriorating before the intervention, was sta- after PTRAS, more patients were cured of hypertension
in the group with an initially normal SCr value [28], as inbilized thereafter. Similar results were reported in a
group of 23 patients with RAS whose deteriorating renal our study. Although renal dysfunction has been consid-
ered a marker of adverse outcomes after PTRAS [32],function was stabilized by PTRAS [23]. Our results ex-
tend these findings by demonstrating that beneficial ef- our results showing a significant improvement in GFR
in patients with RAS and renal function impairment infects on renal function may be anticipated in selected
patients treated with PTRAS if their baseline renal func- a sample of subjects younger than other reported series,
raise questions about the prognostic role of other mark-tion is abnormal. Whether this result may imply an over-
all improvement in prognosis, based on the well-known ers like hypertension control (worse in those with pre-
viously altered GFR), age, and comorbidity. Studies de-prognostic value of serum creatinine, or conversely, as
serum creatinine was not entirely normalized, the rela- signed with hard end points, prolonged follow-up and
controlled interventions over the main treatable risk fac-tive prognostic value of the baseline creatinine may be
more important than serum creatinine at outcome after tors (such as hypertension, dyslipidemia, diabetes) are
needed to find these answersPTRAS, remains a matter of speculation, but this issue
deserves further study. Dorros et al did not address that
Conclusionspoint, and they underscored the importance of PTRAS
as a revascularization procedure before the onset of renal Two conclusions can be drawn from our study that, if
confirmed, may help select patients most likely to benefitdysfunction in order to improve BP control, preserve or
prevent renal function deterioration and patient survival from intervention. First, PTRAS can reduce BP and in-
crease GFR over a mean of one year in a group of[32]. Based in our observations, the improvement of
GFR after PTRAS in patients with decreased renal func- patients carefully selected to have high grade anatomical
RAS that is hemodynamically significant. Second, amongtion resulting in a partial restoration or an interruption
of the downward slope of renal function along the spon- such selected patients, those with initially normal to
mildly impaired renal function may anticipate an im-taneous evolution of ischemic nephropathy—as reported
by Harden et al [23] and Watson et al [34]—supports a proved BP after intervention, whereas those with initially
moderate to severely impaired renal function may antici-valuable therapeutic role for PTRAS in such patients,
possibly delaying the onset of ESRD. pate an improved GFR. This latter conclusion remains
strongly supported after the correction for the RTMAn interesting finding was the discordance between
the beneficial effects of PTRAS on BP and GFR in the phenomenon in baseline GFR data.
analysis of subgroups. The group with an initially higher
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